The objective of this study was to evaluate the effect of hormone replacement therapy in 261 postmenopausal women in Kuwait 1 year after starting treatment. The investigations were carried out from June 1992 to June 1994. Combined estrogen and progesterone were used by 50.6% of the women while estrogen implants were used by 18%, transdermal therapeutic system (TTS) patches by 10.3%, natural estrogen by 10.0%, Livial by 6.1%, and estrogen cream by 5.0%. The side effects of HRT were few and mild. Nine of the 27 patients on TTS patch had allergic skin reactions. Significant reduction in the vasomotor symptoms of hot flushes, night sweats and palpitations was achieved in 80-90% of the patients; 31-37% experiencing total elimination of symptoms. Although there was appreciable reduction in the musculoskeletal, psychological and sexual dysfunction symptoms, relief was significantly better for the vasomotor symptoms (p < 0.01). There was a significant reduction in the levels of FSH and LH, and an increase in estrogen levels (p < 0.001), but no significant change was recorded in the lipoprotein profile (p > 0.05). In conclusion, hormone replacement therapy has a significant place in the alleviation of climacteric symptoms in this community.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.